Working… Menu

Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01816672
Recruitment Status : Terminated (Low enrollment)
First Posted : March 22, 2013
Last Update Posted : October 21, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine if AutoloGel platelet rich plasma used on non healing diabetic foot ulcers Wagner gd. 1 and 2 is more effective then the usual and customary care

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Device: AutoloGel Other: Usual and Customary Care Not Applicable

Detailed Description:
Autologel is a platelet-rich plasma gel used in the treatment of no-healing chronic wounds. Prospective observational studies of the effectiveness of Autologel have demonstrated promising results in regard to the healing of diabetic foot ulcers including severe Wagner grade 3 and 4 ulcers. The aim of the current trial is to compare the efficacy, measured as wound healing in a single-blind (assessor) randomized controlled trial, of usual and customary care with and without Autologel in treating Wagner 1 and 2 diabetic foot ulcers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center, Prospective, Clinical Trial Comparing the Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner 1 and 2 Diabetic Foot Ulcers
Study Start Date : April 2013
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: AutoloGel
AutoloGel treatment
Device: AutoloGel
Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
Other Name: Autologel System

Usual and Customary Care
Standard of care
Other: Usual and Customary Care
Standard of care treatment twice weekly for 2 weeks then weekly
Other Name: Standard of care clinically indicated

Primary Outcome Measures :
  1. Compare time to heal in Wagner 1 and 2 diabetic foot ulcers at 12 weeks treated with AutoloGel versus usual and customary care [ Time Frame: 12 weeks ]
    Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements confirmed at consecutive study visits 2 weeks apart. Initial diagnosis of healing by unblinding Principal Investigator will be confirmed by an independent blinded observer using digital photography, planimetry data and wound measurements

Secondary Outcome Measures :
  1. Assess wound healing trajectory and change in Chronic Wound quality of Life W-QOL scores: and to assess the comparative safety of AutoloGel and usual and customary care [ Time Frame: 13 weeks ]
    QOL tool administered prior to and at the end of treatment to document the impact of the wound on the subject's life and whether treatment interventions helped a return to improved functioning.

  2. Number of patients with adverse events as a measure of tolerability [ Time Frame: 12 weeks ]
    Frequency and severity of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Medicare eligible
  2. ≥18 years of age
  3. Type I or II diabetes requiring medical treatment as determined by the physician
  4. The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (index ulcer) is a Wagner 1 or 2 Diabetic Foot Ulcer (DFU; see Appendix 9 for Wagner Classification) that is located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces but not on the heel). Subjects who have heel ulcers may be included if another, eligible wound is the index ulcer
  5. For subjects with potentially multiple eligible DFUs, the largest ulcer will be selected. There must be at least 4 cm between the index ulcer and other ulcers; if all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure)
  6. Debrided ulcer size between 0.5 cm2 and 20 cm2
  7. Demonstrated adequate offloading regimen
  8. Duration ≥ 1 month at first visit (screening period)
  9. Subject must be willing to comply with the Protocol, which will be assessed by enrolling clinician.

Exclusion Criteria:

  1. Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin
  2. Wagner 3, 4, or 5 DFU (see Appendix 9 for Wagner Classification) Page 15 of 58
  3. Any clinically infected index ulcer that is apparent on Day 0. The presence of infection is defined by ≥ 2 classic findings of inflammation (erythema, warmth, tenderness, pain, or induration) or purulent secretions (Lipsky, 2012, or see Appendix 4)
  4. Presence of another wound that is concurrently treated and might interfere with index wound
  5. Ulcer not of DFU pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology)
  6. Presence of underlying osteomyelitis, or if osteomyelitis is suspected
  7. Received systemic corticosteroids or immunosuppressive agents, hyperbaric oxygen therapy (HBOT), electrostimulation, growth factors, or any cell or tissue-derived products for wounds during the 30 days preceding the screening visit; received radiation therapy or chemotherapy within previous 6 months
  8. Any malignancy other than non-melanoma skin cancer
  9. Ischemic ulcer defined as an ankle brachial index (ABI; handheld or Arterial Doppler) < 0.8 (note: if ABI is ≥ 1, then an skin perfusion pressure (SPP) or transcutaneous oximetry (TCOM) must be performed or the subject cannot be enrolled), TCOM < 30 mm Hg, or SPP < 30 mm Hg; toe pressure < 45 mm Hg. These measurements may be concurrent with the initial evaluation of the index ulcer or obtained within 90 days of study enrollment if done prior to that concurrence.
  10. Subject has radiographic evidence consistent with diagnosis of active Charcot foot
  11. Untreated Charcot foot or DFUs associated with a treated Charcot deformity in which reconstruction or offloading has not taken place
  12. Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)
  13. Ulcer area decreases by ≥ 30% during 2-week screening/run-in period
  14. Subjects who are cognitively impaired and do not have a healthcare proxy
  15. Serum albumin of less than 2.5 g/dL
  16. Plasma Platelet count of less than 100 x 109/L
  17. Hemoglobin of less than 10.5 g/dL
  18. Subject has inadequate venous access for repeated blood draw required for AutoloGel Administration
  19. Subject requires or is anticipated to require interventions directed at improvement of arterial perfusion to affected area.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01816672

Layout table for location information
United States, Mississippi
Forest General Hospital
Hattiesburg, Mississippi, United States, 39401
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Cytomedix Identifier: NCT01816672     History of Changes
Other Study ID Numbers: CM001
First Posted: March 22, 2013    Key Record Dates
Last Update Posted: October 21, 2016
Last Verified: October 2016
Keywords provided by Cytomedix:
Wagner 1
Wagner 2
Non healing diabetic foot wound
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases